Related Experiment Video

Updated: Aug 16, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
13:59

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds

Published on: August 18, 2023

Docetaxel/trastuzumab combination therapy for the treatment of breast cancer

Jean-Marc Nabholtz1, Joseph Gligorov

  • 1Breast Cancer Research Institute, La Prandie, 24290 Valojoulx, France. jmnabholtz@hotmail.com ,

Expert Opinion on Pharmacotherapy
|August 10, 2005
PubMed

Insights

Combining trastuzumab (a HER-2 targeted antibody) with docetaxel chemotherapy shows significant promise for HER-2-positive breast cancer treatment, including in advanced stages.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Human epidermal growth factor receptor-2 (HER-2) is overexpressed in about 20% of breast cancers.
  • Trastuzumab, a monoclonal antibody, targets HER-2 and has shown clinical benefit in HER-2-positive breast cancer.
  • Docetaxel is a potent chemotherapy agent for both metastatic and early-stage breast cancer.

Purpose of the Study:

  • To review clinical trial results of combining trastuzumab and docetaxel for HER-2-positive breast cancer.
  • To evaluate triple combinations including docetaxel, trastuzumab, and platinum salts.

Main Methods:

  • Review of clinical trials investigating the combination of trastuzumab and docetaxel.
  • Analysis of studies involving triple combinations with platinum salts.

Main Results:

  • Preclinical data suggest synergistic effects between trastuzumab and docetaxel.
  • Clinical results indicate that these combinations are highly active.
  • The combinations show promise in both metastatic and adjuvant settings for HER-2-positive breast cancer.

Conclusions:

  • The combination of trastuzumab and docetaxel is a promising therapeutic strategy for HER-2-positive breast cancer.
  • Triple combinations including platinum salts may offer further efficacy.
  • These regimens represent active therapies for advanced and potentially early-stage HER-2-positive breast cancer.

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.